Ohnhaus E E, Vozeh S, Nüesch E
Schweiz Med Wochenschr. 1975 Dec 20;105(51):1782-3.
Digoxin absorption was investigated in 7 patients suffering from severe right cardiac failure. After successful treatment and disappearance of the symptoms of right cardiac failure, the study was repeated in the same patients. Tritium-labelled digoxin in a dose of 0.1 mg as a solution, and non-labelled digoxin as a 0.25 mg tablet, were given to the patients in the fasting state. Blood samples were taken at specified time intervals up to 120 h and the urine was collected during the same period. The concentrations of digoxin in plasma and urine were measured in a liquid scintillation counter. The unlabelled digoxin was estimated by radioimmunoassay. The concentrations obtained in the plasma and urine were used to compute pharmacokinetic parameters. There was no significant difference in the plasma concentration curves in severe right cardiac failure and after successful treatment, nor did the calculated pharmacokinetic parameters differ significantly. Inhibition of digoxin absorption in severe right cardiac failure therefore seems unlikely.
对7例严重右心衰竭患者的地高辛吸收情况进行了研究。在成功治疗且右心衰竭症状消失后，对同一批患者重复进行了该研究。给处于空腹状态的患者服用剂量为0.1 mg的氚标记地高辛溶液以及一片0.25 mg的未标记地高辛片剂。在长达120小时的特定时间间隔采集血样，并在同一时期收集尿液。使用液体闪烁计数器测量血浆和尿液中的地高辛浓度。通过放射免疫测定法估算未标记地高辛。所获得的血浆和尿液浓度用于计算药代动力学参数。严重右心衰竭时和成功治疗后的血浆浓度曲线无显著差异，计算得到的药代动力学参数也无显著差异。因此，严重右心衰竭时地高辛吸收受抑制的情况似乎不太可能。
